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Aims Genome-wide association studies have previously identified INSIG2 as a candidate gene for plasma low-density lipo-
protein cholesterol (LDL-c). However, we suspect a role for CCDC93 in the same locus because of its involvement
in the recycling of the LDL-receptor (LDLR).
...................................................................................................................................................................................................
Methods
and results
Characterization of the INSIG2 locus was followed by studies in over 107 000 individuals from the general popula-
tion, the Copenhagen General Population Study and the Copenhagen City Heart Study, for associations of genetic
variants with plasma lipids levels, with risk of myocardial infarction (MI) and with cardiovascular mortality. CCDC93
was furthermore studied in cells and mice. The lead variant of the INSIG2 locus (rs10490626) is not associated
with changes in the expression of nearby genes but is a part of a genetic block, which excludes INSIG2. This block
includes a coding variant in CCDC93 p.Pro228Leu, which is in strong linkage disequilibrium with rs10490626
(r2 > 0.96). In the general population, separately and combined, CCDC93 p.Pro228Leu is dose-dependently
associated with lower LDL-c (P-trend 2.5  10-6 to 8.0  10-9), with lower risk of MI (P-trend 0.04–0.002) and
lower risk of cardiovascular mortality (P-trend 0.005–0.004). These results were validated for LDL-c, risk of both
coronary artery disease and MI in meta-analyses including from 194 000 to >700 000 participants. The variant is
shown to increase CCDC93 protein stability, while overexpression of human CCDC93 decreases plasma LDL-c
in mice. Conversely, CCDC93 ablation reduces LDL uptake as a result of reduced LDLR levels at the cell
membrane.
...................................................................................................................................................................................................
Conclusion This study provides evidence that a common variant in CCDC93, encoding a protein involved in recycling of the
LDLR, is associated with lower LDL-c levels, lower risk of MI and cardiovascular mortality.
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Introduction
Atherosclerotic cardiovascular disease is a major cause of morbidity
and mortality1 for which low-density lipoprotein cholesterol (LDL-c)
is a well-established causal risk factor.2–5 Genome-wide association
studies have identified numerous regions in the genome (loci) that are
primarily associated with plasma LDL-c concentration.6–10 For ap-
proximately half of the LDL-c associated loci, it is not known which
mechanisms underlie these associations, emphasizing that our know-
ledge of LDL metabolism is far from complete.
Here, we focus on the single nucleotide polymorphism (SNP)
rs10490626, on the second chromosome at position 118835841
(GRCh37). The T allele is found in 9% of non-Finnish Europeans
(http://gnomad.broadinstitute.org) and has been reported to be asso-
ciated with reduced plasma LDL-c levels.9,10 This variant is located in
the locus 2q14 upstream of the INSulin Induced Gene 2 (INSIG2)
which is implicated in the regulation of cholesterol synthesis. Loss of
Insig2 does, however, not affect plasma cholesterol levels in mice.11
This, combined with recent insight, led us to suspect a role for coiled-
coil domain-containing protein 93 (CCDC93), another gene in this
locus. This because we have recently shown that CCDC93 partici-
pates in an evolutionary conserved multiprotein complex, annotated
as the CCC complex (COMMD/CCDC22/CCDC93; see Supple-
mentary material online for additional information), that orchestrates
the endosomal recycling of the LDL-receptor (LDLR).12,13 Loss of
proteins of the CCC complex studied thus far causes hypercholes-
terolaemia in mammals including man.
The current study contributes to the unravelling of a mechanism
that offers an explanation of how rs10490626 is associated with
reduced plasma levels of LDL-c and protection against myocardial in-
farction (MI) and death from cardiovascular disease. Several lines of
evidence suggest that stabilization of the endosomal sorting machin-
ery through a coding variant of CCDC93 increases LDLR recycling,
thereby lowering levels of LDL-c in plasma.
Methods
A flowchart of epidemiological and genetic analyses is shown in
Supplementary material online, Figure S1. A brief description of the meth-
ods is provided below. For more detailed descriptions refer
Supplementary material online, Appendix.
Characterization of the chromosomal region
2q14
Expression quantitative trait loci (eQTL) analyses aim to connect SNPs
with the expression of genes. We first tested whether the T allele of
rs10490626 was associated with expression levels of protein-coding
genes in the locus 2q14 (within 1 Mb surrounding this SNP) using a public-
ly available mRNA dataset (GTEx; V7 release).14 In addition, we used an
eQTL dataset from Biobank-based Integrative Omics Studies (BIOS)
Consortium of the BBMRI-NL (http://wiki.bbmri.nl/wiki/BIOS_bios)
which is composed of whole blood samples from 2116 donors.
Pairwise linkage disequilibrium (LD) values were obtained from the
Phase 3 release of the 1000 Genomes project.15 In addition, LD between
rs10490626 and rs17512204 (CCDC93 p.Pro228Leu) was determined in
individuals in the studied populations (see below).
Participants
We included individuals from two prospective studies of the Danish gen-
eral population, The Copenhagen General Population Study (CGPS) and
The Copenhagen City Heart Study (CCHS) that have been described in
detail elsewhere.16 All individuals were white and of Danish descent.
Combining the participants in the CGPS and CCHS yielded a total of
107 063 participants at baseline. During a mean follow-up of 36 years
(range: <1–40 years) which ended in March 2017, MI developed in 5291
individuals and 3635 died from ischaemic cardiovascular disease. In both
studies, follow-up was 100% complete, i.e. we did not lose track of a sin-
gle individual. DNA was available for all individuals, and lipid values were
available for more than 98%.
The study was approved by institutional review boards and Danish
ethics committees and was conducted according to the principles of the
Declaration of Helsinki. Written informed consent was obtained from all
individuals. For additional information on participation rates, clinical end-
points, laboratory analyses, and other covariates (Supplementary material
online, Appendix).
Genotyping and statistical analyses
CCDC93 p.Pro228Leu (rs17512204; C>T) which is in complete LD with
rs10490626 (see Results section), was genotyped using an ABI PRISM
7900HT Sequence Detection System (Applied Biosystems Inc., Foster
City, CA, USA) and TaqMan-based assays.
Data were analysed using Stata/S.E. 14.0. The v2 test evaluated Hardy–
Weinberg equilibrium. To compare baseline characteristics by CCDC93
p.Pro228Leu (rs17512204) genotype, we used Cuzick’s test for trend.
For trend tests, genotypes were coded 0, 1, and 2. The genotype associ-
ated with the highest LDL-c levels was used as the reference (coded 0).
P-values were by tests for trend from linear regression models. Cox pro-
portional hazards regression models, using age as time scale and delayed
entry (left truncation) which implies that age is automatically adjusted for,
were used to estimate hazard ratios for MI and cardiovascular mortality
as a function of CCDC93 p.Pro228Leu (rs17512204) genotypes.
Multifactorial adjustments were for well-known risk factors for MI: age,
gender, body mass index, hypertension, diabetes mellitus, physical activ-
ity, smoking, alcohol consumption, hormone replacement therapy
Translational perspective
The present study shows that a common genetic variant in the gene CCDC93 is associated with lower plasma low-density lipoprotein choles-
terol (LDL-c) levels and a corresponding lower risk of myocardial infarction in the general population. This study suggests that endosomal traf-
ficking and/or recycling of LDL-receptor could be a target for pharmaceutical intervention.
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(women only), and lipid-lowering therapy. Analyses were conducted
from 1 January 1977 (start of the national Danish Patient Registry and the
national Danish Causes of Death Registry) through March 2017.
Finally, we performed meta-analyses of CCDC93 rs17512204
(p.Pro228Leu) on LDL-c, risk of coronary artery disease (CAD) and MI
combining data from the Danish general population with data from: (i)
the Global Lipids Genetics Consortium (Ref.9 and http://lipidgenetics.org)
for LDL-c; (ii) summary data from the UK Biobank (http://geneatlas.roslin.
ed.ac.uk) and CARDIoGRAMplusC4D 1000 Genomes (Ref.17 and http://
www.cardiogramplusc4d.org/data-downloads/) for risk of ischaemic heart
disease and MI using the ‘metan’ command in Stata.
In vitro characterization of CCDC93
Pro228Leu
FLAG-tagged CCDC93 (pcDNA3.1-CCDC93-FLAG) was purchased
from Genscript (OHu01865D). pcDNA3.1-CCDC93-p.Pro228Leu-FLAG
was generated with the QuikChange II Site-Directed Mutagenesis Kit.
Wildtype (CCCD93WT) and CCDC93 p.Pro228Leu were transiently
overexpressed in HEK293T cells. The protein stability of both variants
was assessed after blocking protein synthesis at an optimal concentration
of cycloheximide that did not affect cell viability, i.e. 50mg/mL (CHX –
Sigma C4859). In short, 24 h after transfection, cells were cultured in me-
dium supplemented with cycloheximide and harvested at sequential time
points (from 4 to 36 h). Cell lysates were used for western blotting using
anti-FLAG antibody. Statistical comparison of protein concentrations be-
tween CCDC93WT vs CCDC93p.Pro228Leu was calculated using the
Student’s t-test.
Overexpression of human CCDC93 in
Ldlrþ/mice
Liver overexpression of human CCDC93 (hCCDC93) in Ldlrþ/2 mice
(n = 5) was achieved through intravenous administration of adeno-
associated virus 8 (AAV8) harbouring hCCDC93, or with a matched viral
dose of empty AAV8 particles as controls (n = 5). Animals were single
housed and fed a standard chow diet. Three weeks after injections, ani-
mals were fasted and sacrificed by cardiac puncture under anaesthesia.
Plasma cholesterol concentrations in the main lipoprotein classes [very
low-density lipoprotein, LDL, and high-density lipoprotein (HDL)] were
determined using fast protein liquid chromatography in plasma of each
animal and compared using the Student’s t-test. This study was approved
by the Institutional Animal Care and Use Committee, University of
Groningen (the Netherlands).
Generation and characterization of a
CCDC93 deficient liver cell line
Huh7 CCDC93 knockout cells (CCDC932/2) were generated using
CRISPR/Cas9 editing technology.18 To quantify protein concentration,
we used custom targeted liquid chromatography-mass spectrometry
(LC/MS) based proteomic assays.12,13
Low-density lipoprotein uptake capacity of the cells [Huh7
CCDC932/2 vs. wild-type (wt)] was evaluated using DiI-labelled LDL.
Cells were deprived of serum for 16 h and subsequently incubated with
DiI-LDL (5 mg/mL) containing medium for 2.5 h. After washing, fixation,
and mounting, DiI-LDL uptake was quantified and normalized by fluores-
cent microscopy in a blinded fashion. More than 700 cells per condition
were recorded.
To assess the level of the LDLR at the cell surface, we used a biotinyla-
tion assay which targets proteins at the plasma membrane. Briefly, cells
were incubated with biotin and lysed. The biotinylated membrane frac-
tion was isolated using neutravidin beads. Both, membrane and whole cell
lysate fractions were analysed using western blotting. For both LDL up-
take and biotinylation assays, the Student’s t-test was used to compare
different conditions.
Results
Genetic association and characterization
of the 2q14 locus
Among SNPs spanning the region of chromosome 2 (locus 2q14)
(Figure 1A), rs10490626 shows the strongest association (y axis,
-log10 P-value) with LDL-c plasma levels. The respective SNP is
located 246 kb downstream of DDX18, 64 kb upstream of CCDC93,
and 10 kb upstream of INSIG2 (x axis, Figure 1A). We found that
rs10490626 is part of an LD block of 200 kb (r2 > 0.8, data from the
Phase 3 release of the 1000 Genomes project15) that includes
CCDC93, but not INSIG2 and DDX18 (Figure 1A). This LD block
includes rs17512204, a SNP that leads to the substitution of a leucine
for a proline residue at position 228 of CCDC93 (NM_019044.4:
rs17512204_c.683C>T, p.Pro228Leu). Importantly, rs17512204 is in
complete LD with rs10490626 (r2 = 0.96, P-value: <0.0001; data
from 1000 Genomes project) (Figure 1A) implying that these SNPs
are co-inherited.
Using the GTEx Consortium mRNA dataset (Release V7), we
assessed whether rs10490626 is associated with the expression of
DDX18, CCDC93, or INSIG2. In line with previous findings,9 the data
show that rs10490626 is probably not an eQTL (plotted association
data in adipose, liver, and intestine, Supplementary material online,
Figure S2). Taken the small number of samples of these relevant tis-
sues (n = 385, 313, 153, and 125 for subcutaneous adipose tissue, vis-
ceral adipose tissue, liver, and intestine, respectively) combined with
the frequency of rs10490626, these eQTL analyses were, however,
underpowered. Of note, GTEx suggests that rs10490626 is an eQTL
in testis tissue for the pseudogene HTR5BP, which is exclusively
expressed in testis (data not shown) and is very unlikely relevant in
regard to the plasma-cholesterol metabolism.
In a next step, we took advantage of the fact that DDX18, CCDC93,
and INSIG2 are all ubiquitously expressed [according to GTEx14
(https://www.gtexportal.org) and The Human Protein Atlas (https://
www.proteinatlas.org)19] and ran an eQTL analysis using RNA-seq
data set of whole human blood (n = 2116).20 Figure 1B shows that
rs10490626 is not associated with changes in the expression of
DDX18, (P = 0.31), CCDC93 (P = 0.17), or INSIG2 (P = 0.94) in blood,
which suggests that rs10490626 is not an eQTL for the genes studied.
CCDC93 genotype, plasma lipids,
lipoproteins, and apolipoproteins in the
Danish general population cohorts
In agreement with publicly available data, LD between the minor
alleles of the intergenic lead GWAS SNP, rs10490626 and
rs17512204 (CCDC93 p.Pro228Leu) was near complete (r2 = 0.98) in
both the CGPS and the CCHS population cohorts, thereby validating
the use of the latter variant in our study. Baseline characteristics of
the 107 063 individuals from the CGPS and CCHS, combined and in-
dividually, as a function of CCDC93 p.Pro228Leu genotype
(rs17512204; C>T) are shown in Supplementary material online,
CCDC93, LDLR and cardiovascular protection 3
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..Tables S1–S3. Characteristics as a function of genotype were similar.
In agreement with the corresponding lower LDL-c levels (Figure 2A,
second panel), the use of lipid-lowering therapy tended to be slightly
less frequent as a function of increasing number of T-alleles (P for
trend < 0.05) (Supplementary material online, Table S1). Taken to-
gether, these data suggest that the genetic data are largely uncon-
founded by the main known measured risk factors for MI. Finally,
genotype distribution did not differ from Hardy–Weinberg equilibrium.
CCDC93 p.Pro228Leu (rs17512204; C>T) was associated with
lower plasma levels of total cholesterol up to 0.9% (-0.05 mmol/L, P
for trend = 4.8  10-8), LDL-c up to 2.2% (-0.07 mmol/L, P for
trend = 8.0  10-9), and apolipoprotein B up to 1.0% (-1.14 mg/dL, P
for trend = 3.4  10-6), in homozygotes for the minor T-allele vs.
non-carriers (Figure 2A, Panels 1–3 from left) but was not associated
with HDL cholesterol, apolipoprotein AI (ApoAI), triglycerides,
calculated remnant cholesterol (which mirrors triglycerides), or lipo-
protein(a) (Figure 2A, Panels 4–7; data not shown for calculated rem-
nant cholesterol). Results were similar for the CGPS and the CCHS
separately (Supplementary material online, Figure S3). In individuals
who were not on lipid-lowering therapy (N = 95 512), total choles-
terol, LDL-c, and apolipoprotein B were even further reduced (com-
pare Figure 2A and Supplementary material online, Figures S3 with S4).
CCDC93 genotype and risk of myocardial
infarction
The multifactorially adjusted hazard ratios for MI decreased stepwise
as a function of rs17512204 genotype to 0.88 (95% confidence inter-
val: 0.81–0.96) in CT heterozygotes and 0.67(0.39–1.16) in TT homo-
zygotes (P for trend = 0.002) (Figure 2B). In the individual studies, the
corresponding hazard ratios were 0.92 (0.83–1.01) and 0.67 (0.36–
A
B
Figure 1 Genetic association with low-density lipoprotein cholesterol and fine mapping of the locus 2q14. (A) Illustrates the association with low-
density lipoprotein cholesterol (y axis) for single nucleotide polymorphisms spanning the region of chromosome 2 including CCDC93, DDX18, and
INSIG2, and the pairwise linkage disequilibrium between rs10490626 and other single nucleotide polymorphisms. Red colour indicates strong linkage
disequilibrium (r2 > 0.8). As shown, rs10490626 is in complete linkage disequilibrium (R2 > 0.80) with rs17512204 (CCDC93 p.Pro228Leu) and with
other non-coding single nucleotide polymorphisms spanning CCDC93.9 Plots were generated from publicly available data and the online locuszoom
tool (http://locuszoom.org/). (B) Normalized gene expression for DDX18, CCDC93, and INSIG2 as a function of rs10490626 G>A genotypes showing
that genotypes are not associated with levels of gene expression within the 2q14 locus: DDX18 (P=0.314), CCDC93 (P=0.166), and INSIG2 (P=0.94)
when using eQTL dataset from BIOS-consortium containing 2116 blood samples (B).
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..1.24) in the CGPS (P for trend = 0.04), and 0.77 (0.63–0.93) and 0.71
(0.23–2.20) in the CCHS (P for trend = 0.007) (Supplementary
material online, Figure S5A and C).
CCDC93 genotype and cardiovascular
mortality
The multifactorially adjusted risk of cardiovascular mortality
(N = 4126 events) decreased stepwise as a function of rs17512204
genotype to 0.87 (95% confidence interval: 0.78–0.97) in CT hetero-
zygotes and 0.64 (0.33–1.22) in TT homozygotes (P for
trend = 0.004) (Figure 2C). Results were similar in the CGPS and
CCHS separately (Supplementary Figure S5B and D).
Meta-analyses on low-density lipoprotein
cholesterol, risk of ischaemic heart
disease, and myocardial infarction
In meta-analyses of CCDC93 rs17512204 (p.Pro228Leu) on LDL-c
including data from the Global Lipids Genetics Consortium (Ref.9
and http://lipidgenetics.org) and the Danish general population
(CGPS þ CCHS), the per T-allele reduction in LDL-c was -0.05
standard deviation for the inversed normalized distribution of LDL-c
(95% CI: -0.06 to -0.04) using both random and fixed effects models
(Figure 3A), corresponding to an approximate reduction of
0.05 mmol/L (2 mg/dL) in our study. There was no evidence of het-
erogeneity between studies (I2 = 0%, P = 0.84).
In meta-analysis of risk of CAD, the per T-allele odds ratio was
0.97 (0.94–0.99) in both random and fixed effects models (Figure 3B).
CAD was self-reported heart attack or MI in the UK Biobank. In the
Danish general population, this diagnosis corresponded best to is-
chaemic heart disease and included angina pectoris and MI based on
International Classification of Diseases codes (ICD8: 410–414 and
ICD10: I20–25); MI was independently validated—for a detailed de-
scription see Supplementary material online, Methods. In
CARDIoGRAMplusC4D 1000 Genomes (Ref.17 and http://www.car
diogramplusc4d.org/data-downloads/), CAD was based on diagnostic
criteria in 48 different studies which were harmonized across studies
(for a detailed description of diagnoses in the individual studies see
Figure 2 Plasma lipid levels and risk of myocardial infarction and cardiovascular mortality as a function of CCDC93 P228L (rs17512204; C>T) geno-
type in the general population. Data are from the Copenhagen General Population Study and the Copenhagen City Heart Study cohorts (combined
107 063 participants). (A) P-values were tested for trend using linear regression models. (B and C) Cox proportional hazards regression models using
age as time and delayed entry (left truncation) were used to estimate hazard ratios for myocardial infarction and cardiovascular mortality as a function
of genotype. Hazard ratios were adjusted for age (left panel) or multifactorially adjusted for age, gender, body mass index, hypertension, diabetes mel-
litus, physical activity, smoking, alcohol consumption, hormone replacement therapy (women only), and lipid-lowering therapy. P-values are for tests
for trend for hazard ratios. N, number of individuals.
CCDC93, LDLR and cardiovascular protection 5
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Figure 3 Meta-analyses of low-density lipoprotein cholesterol, risk of coronary artery disease, and myocardial infarction per rs17512204 C>T
(CCDC93 p.P228L) T-allele. (A) Meta-analysis summarizing effect size on low-density lipoprotein cholesterol per T-allele. Global Lipids Genetics con-
sortium (Ref.9 and http://lipidgenetics.org/). (B) Meta-analysis summarizing risk of coronary heart disease per T-allele. CARDIoGRAMplusC4D 1000
Genomes (Ref.17 and http://www.cardiogramplusc4d.org/data-downloads/); UK Biobank summary data from GeneAtlas (http://geneatlas.roslin.ed.ac.
uk). The diagnosis coronary artery disease was self-reported heart attack/myocardial infarction in the UK Biobank (http://biobank.ctsu.ox.ac.uk/crys
tal/field.cgi?id=20002), coronary artery disease from CARDIoGRAMplusC4D 1000 Genomes (data as published in Ref.17) and ischaemic heart dis-
ease (including angina pectoris based on ICD code, and myocardial infarction based on ICD code and independently validated to a validity >99%). (C)
Meta-analysis summarizing risk of myocardial infarction per T-allele. Myocardial infarction was myocardial infarction in the UK Biobank (ICD10 code
I21 acute myocardial infarction, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=41202; summary data from http://geneatlas.roslin.ed.ac.uk) myocardial
infarction from sub-phenotype analysis in CARDIoGRAMplusC4D, and myocardial infarction (ICD8: 410 and ICD10 I21 and I22; validated to a valid-
ity of >99% by cardiologists). In all three meta-analyses, horizontal lines correspond to 95% confidence intervals by forest plots. Diamonds and red
broken vertical lines represent the summary estimates. The width of the diamonds represents the confidence intervals for the summary estimates.
Grey shaded areas correspond to the weight of the study; weights on the graphs are from random effects models. Overall effect sizes are Cohen’s d
with 95% confidence intervals. aCopenhagen General Population Study and Copenhagen City Heart Study combined.
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Ref.17 Supplementary material online, Notes). There was no evidence
of heterogeneity between studies (I2=0%, P = 0.96) (Figure 3B).
In meta-analysis of MI, the overall odds ratio for MI per T-allele
was 0.95 (0.90–0.99) using a random-effects model, and 0.95 (0.92–
0.98) using a fixed-effects model (Figure 3C). There was modest, non-
significant heterogeneity between studies (I2 = 53%, P = 0.12) with
overlapping confidence intervals. The estimates became significant
for both CARDIoGRAMplusC4D 1000 Genomes [0.96 (0.92–0.99)]
and our study [0.88 (0.81–0.96)], but not different from unity for the
UK Biobank, on the hard endpoint MI.
Sensitivity analyses
To determine whether CCDC93 p.Pro228Leu affected other pheno-
types than LDL-c which might additionally explain the effect on risk
of CAD, MI, and cardiovascular mortality, or affect other endpoints,
we first determined the per T-allele effect on 34 different phenotypes
and an additional five endpoints in our own study (Supplementary
material online, Figure S6). Only total cholesterol, LDL-c, apolipopro-
tein B, and risk of MI were significant. Second, we collected all avail-
able data from GWAS studies and chip data from the Cardiovascular
Disease Knowledge Portal (29 March 2019; http://broadcvdi.org/
variantInfo/variantInfo/rs17512204) (for a description of the studies
included, see legend to Supplementary material online, Figure S7). In
these meta-analyses including 30 phenotypes or endpoints, the per
T-allele effect reached genome-wide significance for total cholesterol
and LDL-c only (Supplementary material online, Figure S7). Third, we
included summary ‘phewas’ (phenomewide association study) data
from the UK Biobank for rs17512204 (http://geneatlas.roslin.ed.ac.
uk). In that study, ‘high cholesterol’ was the most significant hit (note
that the reference allele in the UK Biobank was the wild-type G-allele,
implying that the results are opposite using the minor T-allele as the
reference in our study, i.e. low cholesterol), while there were indica-
tions that the variant might affect anthropometric parameters (for T-
allele: increased leg fat mass, increased weight and hip circumference,
but also increased basic metabolic rate, and lower physical activity)
(Supplementary material online, Table S4). Combined, these latter
findings are unlikely to reduce risk of CAD.
Proportional risk of coronary artery
disease and myocardial infarction as a
function of per allele genetically
determined increase in low-density
lipoprotein cholesterol in the general
population (CCHS and CGPS)
The proportional risk of CAD and MI as a function of the per allele
genetically determined increase in LDL-c for variants in well-known
LDL-c genes (NPC1L1, PCSK9, ABCG8, APOB, and the LDLR) in the
CCHS and CGPS is shown in Supplementary material online, Figure
S8 and compared to the effect for CCDC93 p.Pro228Leu (G-allele).
First, the proportional risk of CAD and MI for CCDC93 p.Pro228Leu
(G-allele) was comparable to that of other LDL-c genes. Second, per
allele risk of CAD for genetic variants in these genes was similar to
risks reported in the EAS consensus paper. These data together with
data from the meta-analyses suggest that CCDC93 p.Pro228Leu is
likely associated with risk of CAD and MI through the LDL-c effect
per se. Finally as expected, risk of MI, a more valid endpoint, was
higher than risk of CAD for most variants in our study, and therefore,
these two endpoints are not directly comparable, as also shown for
CARDIoGRAMplusC4D 1000 Genomes in the meta-analyses
(Figure 3).
CCDC93 p.Pro228Leu increases protein
stability
In a next step, we investigated whether the substitution of a Leucine
for a Proline residue at position 228 in the CCDC93 protein could
explain our genetic and epidemiologic observations. To this purpose,
we transiently overexpressed wildtype (WT) and the p.Pro228Leu
variant in HEK293T cells and investigated their half-life (t1/2) following
incubation with a protein synthesis inhibitor (cycloheximide) (Figure
4A and B). We found that the protein stability of CCDC93
p.Pro228Leu was significantly increased compared to CCDC93WT
after 24 and 36 h (P < 0.05) (Figure 4A and B). This finding suggests
that CCDC93 p.Pro228Leu increases the stability of CCDC93.
Analysis of the whole CCC complex with LC-MS based targeted pro-
teomics furthermore shows that CCDC93 p.Pro228Leu does not af-
fect the stoichiometry of CCC complex (Supplementary material
online, Figure S9).
Increased expression of human CCDC93
in the liver reduces low-density
lipoprotein cholesterol plasma levels in
mice
The increased protein stability of CCDC93 p.Pro228Leu and its asso-
ciation with reduced plasma LDL-c led us to evaluate whether
increasing the levels of wild-type CCDC93 in the liver of mice could
reduce plasma LDL-c. To this end, we injected heterozygous Ldlr
knockout mice (C57Bl6; Jackson Labs) with AAV8 harbouring wild-
type human (h) CCDC93. Three weeks after virus administration, we
observed a 1.8-fold increase of CCDC93 protein in the liver com-
pared to controls (Figure 5A). This was associated with a small but sig-
nificant reduction of LDL-c (P = 0.049) in mice overexpressing
hCCDC93 compared to controls (Figure 5B; Supplementary material
online, Table S5). Using LC-MS based targeted proteomics, we con-
firmed that CCD93 protein concentration was increased (1.6 fold)
(P < 0.001) in liver homogenates, which was accompanied by an in-
crease of the CCC complex component CCDC22 (P < 0.001) in
mice that were treated with AAV8 hCCDC93 compared to controls
(Supplementary material online, Figure S10). Although the overex-
pression of the WT form of CCDC93 does not mimic a gain of func-
tion mutation, these results support the idea that increasing the
amount of hepatic CCDC93 can lower plasma LDL-c.
CCDC93 is required for low-density
lipoprotein receptor recycling and low-
density lipoprotein uptake in liver cells
To validate the role of CCDC93 on endosomal LDLR recycling, we
ablated CCDC93 in human hepatocyte carcinoma cells (Huh7)
(Figure 6A). While this cell line cannot recapitulate all aspects of
human lipid metabolism, the involvement of the CCC complex in
facilitating endosomal trafficking of LDLR has also been shown in
HEK293T, HepG2 as well as primary murine hepatocytes and several
animal models.12,13 Loss of CCDC93 decreased the protein levels of
CCDC93, LDLR and cardiovascular protection 7
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the CCC core components CCDC22 and C16orf62 which is in line
with previous observations12,13 (Figure 6B). This destabilization of the
CCC complex was accompanied by a 50% reduction of LDLR at
the plasma membrane (P < 0.01) (Figure 6C) and a40% reduction in
the uptake of fluorescently labelled LDL (DiI-LDL) compared to con-
trol cells (P < 0.001) (Figure 6D). Combined, these results suggest that
CCDC93 is involved in the endosomal trafficking of LDLR back to
the plasma membrane for the uptake of LDL (Figure 6E).
Discussion
This study suggests that a common variant in CCDC93, p.Pro228Leu
(rs17512204), is associated with increased functioning of the CCC
complex, an endosomal sorting protein complex that orchestrates
LDLR recycling. In agreement with these findings, CCDC93
p.Pro228Leu is associated with per allele lower levels of plasma LDL-
c and a corresponding lower risk of MI and cardiovascular mortality
in over 107 000 individuals from the general population (Take home
figure). These results were validated for LDL-c, risk of both CAD and
MI in meta-analyses including from 194 000 to >700 000 participants.
The LDLR has, since its discovery by Goldstein and Brown in the
‘70s,21 been recognized as the principal regulator of LDL clearance
from the circulation. Its central role in this process is illustrated by
the notion that changes in its transcription,22 internalization,23,24 sta-
bility,25 subcellular localization, and degradation26,27 all affect the con-
centration of LDL-c in blood.
Central to the current study is that Goldstein and Brown also
reported that the LDLR can be re-used up to 100 times after its in-
ternalization into early endosomes.28 On the one hand, the re-use of
LDLR can be prevented by the binding of pro-protein convertase
subtilisin-kexin type 9 (PCSK9) to LDLR. This protein directs the
LDLR to the lysosome compartment for degradation,29 and it has
been established that genetic variants in PCSK9 strongly affect the
capacity of the liver to clear LDL from the circulation. On the other
 wt
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Figure 4 In vitro characterization of the variant CCDC93
Pro228leu. HEK293T cells transiently overexpressing CCDC93WT
or CCDC93p.Pro228Leu were incubated for 0, 4, 12, 24, and 36 h
with an inhibitor of protein synthesis (cycloheximide). Cell lysates
were analysed by western blotting (A) (n = 3). Protein degradation
was quantified, normalized against Beta actin as loading control and
plotted using t = 0 as reference (t = 0: 100%) for each condition B.
The data show that both CCDC93 variants are relatively stable until
12 h, however, CCDC93WT levels drop after 24h (40% de-
crease), whereas CCDC93p.Pro228Leu stays relatively stable be-
yond 36 h after transfection (85% of the initial protein amount).
Statistical comparison was carried out using the Student’s t-test.
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Figure 5 Overexpression of CCDC93 in mice reduces low-
density lipoprotein cholesterol plasma levels. Overexpression of
human (h)CCDC93 in Ldlrþ/2 mice was achieved through intraven-
ous administration of adeno-associated virus 8. Mice were either
injected with AAV8 harbouring human (h)CCDC93 (AAV8-
hCCDC93) (n = 5) or AAV8 empty as controls (n = 5). (A) Protein
overexpression of CCDC93 (1.8-fold increase on average) in the
liver of mice injected with AAV8-hCCDC93 (o/e hCCDC93) com-
pared to controls. Main plasma lipoprotein classes were separated
using fast protein liquid chromatography (x axis fast protein liquid
chromatography fractions) for each individual mouse. Plasma chol-
esterol concentration (y axis in arbitrary units) was measured in
each of the lipoprotein classes. The fractions were determined as
follow: VLDL = fractions from 28 to 34 min; LDL = fractions from
34 to 47 min; HDL = fractions from 47 to 60 min. Mice overex-
pressing hCCDC93 in the liver present a decrease of low-density
lipoprotein cholesterol compared to controls (P = 0.049; B). HDL,
high-density lipoprotein; LDL, low-density lipoprotein; LDLR, LDL-
receptor; VLDL, very low-density lipoproteins.
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hand, little is known about the mechanisms that transport the LDLR
back to the cell membrane for re-use, and how this may affect plasma
LDL-c levels.30 Figure 6E illustrates our current working model.
Endosomal trafficking of different proteins (cargo’s) is a long-
standing topic in cell biology.31,32 We have recently taken a next step
to study this process in vivo.12,13,30,33 These experimental studies in
mice have shown that a loss of proteins of the endosomal sorting ma-
chinery causes hypercholesterolaemia and increased atheroscler-
osis.12,13 In the current study, we provide evidence that it is also
possible to decrease plasma LDL-c in mice through overexpressing
A B
C
Figure 6 Depletion of CCDC93 impaired low-density lipoprotein-receptor recycling and low-density lipoprotein uptake in liver cells. Huh7
CCDC93 knockout cells (CCDC932/2) were generated using CRISPR/Cas9. The inactivation of the gene was validated by western blot (A). Ablation
of CCDC93 (A and B) resulted in a decreased protein levels of the core components of the CCC (COMMD-CCDC22-CCDC93) complex. (B)
CCDC22 and C16orf62 were markedly reduced as well as other satellite components of the complex (COMMD5,7,9,10), whereas total low-density
lipoprotein receptor levels were not affected. Protein measurements were normalized with housekeeping proteins (beta actin and tubulin).
Knockout values were calculated as a percentage of the concentration of proteins in Wt cells. Only statistically significant decreased components of
the CCC complex are presented (B). Plasma membrane and whole cell fractions were isolated using a biotinylation assay and analysed by western
blotting (C). Low-density lipoprotein receptor was found to be strongly reduced in cell surface proteome of CCDC93 knockout cells when compare
with Wt cells (>50% decrease, P < 0.01). Low-density lipoprotein receptor protein quantification was normalized against transferrin receptor as cell
surface loading control. Cells were cultured without serum for 16 h and subsequently incubated with DiI-LDL for 2.5 h and imaged by fluorescence
microscopy. Dil-LDL uptake was measured and normalized per cell (counted with nuclei DAPI staining). More than 700 cells per condition were ana-
lysed and compared. CCDC932/2 cells present impaired uptake of fluorescently labelled low-density lipoprotein (DiI-LDL) compare to controls of
40% (P < 0.001) (D). Low-density lipoprotein-receptor is the central regulator of plasma levels of low-density lipoprotein cholesterol and can be
re-used 100 times after its endocytosis into endosomal network.28 At the endosomes, low-density lipoprotein receptor is sorted for lysosomal deg-
radation, which is promoted through the binding of proprotein convertase subtilisin-kexin type 9 to low-density lipoprotein receptor,29 or low-dens-
ity lipoprotein receptor is recycled back to the plasma membrane for re-use, which is orchestrated by the CCC (COMMD/CCDC22/CCDC93 þ
C16orf62) complex30 (E). CCDC93, coiled-coil domain-containing protein 93; CCDC22, coiled-coil domain-containing protein 22; C16orf62,
chromosome 16 open reading frame 62; COMMD, copper metabolism domain containing; LDLR, low-density lipoprotein receptor; b bellow the de-
tection rate, DiI-LDL 3,3’-dioctadecylindocarbocyanine labelled LDL, DAPI 4’,6-diamidino-2-phénylindole. *P < 0.05; **P < 0.01; NS, not significant.
CCDC93, LDLR and cardiovascular protection 9
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..wild-type CCDC93 albeit it that the effect is small. Others have
shown that over-expression of SNX17, another protein involved in
the endosomal sorting machinery, also enhances LDL uptake via its
positive role on LDLR sorting in cultured cells.34
Evidence that the endosomal LDLR recycling may also be relevant
in humans was so far restricted to rare loss-of-function mutations in
CCDC22 and WASHC5, which cause hypercholesterolaemia but also
developmental defects and intellectual disability.13,35,36 This com-
bined with the notion that a complete loss of components of the
endosomal recycling machinery is lethal in mice12,13,37 indicated that
impairment of this pathway is very harmful. In contrast, the current
study shows that a common genetic variant, presumably associated
with a ‘gain-of-function’, is associated with cardiovascular risk reduc-
tion including a reduction in cardiovascular mortality in the general
population.
In meta-analyses, we found similar CCDC93 p.Pro228Leu per T-al-
lele reductions in LDL-c and risk of CAD in all studies considered,
comparable to data reported in a recent consensus statement from
the European Atherosclerosis Society Consensus Panel.1 Taken
together, the data suggest that the per T-allele reduction in risk of
CAD and MI can be explained by the corresponding observed reduc-
tion in LDL-c.
The per T-allele reduction in risk of MI which is a harder endpoint
than CHD/CAD was 5% overall, similar between studies (overlap-
ping confidence intervals for all studies), and significant in both
CARDIoGRAMplusC4D and in our own study, but not different
from unity in the UK Biobank. The most likely explanation for the lat-
ter finding is that the participation rate in that study was 5.5% (9 mil-
lion invited, 500 000 participants), limiting the representativeness
of the study for the UK general population, and possibly leading to a
healthy participant bias (the participation rates were 61% and 45%,
respectively, in the CCHS and CGPS). The latter is supported by the
observation that the proportion of smokers and the proportion with
no qualifications—reflecting social position—were considerably
lower than in the background population, and that the 5-year mortal-
ity rate was several-fold lower than in the UK population as a
whole.38,39 Furthermore, the frequency of MI in the UK Biobank was
<2% compared to >5% in the Danish general population, suggesting
D
E
Figure 6 Continued.
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that the UK Biobank represents a low-risk population. Therefore, a
common genetic variant, as studied here, which typically associates
with a modest change in risk, is at this point in time unlikely to be
associated with a measurable risk reduction in the UK Biobank with
the current limited follow-up and the low risk at the start of the
study.
It is noteworthy that genome-wide association studies of human
plasma lipid traits have thus far not pointed at a role for the genes
encoding proteins involved in the endosomal recycling process, with
the only exception being for CCDC93 as unveiled in this study. This
can be explained by the fact that this process is primarily regulated at
the post-translational (protein) level,12,13,40 which, in turn, supports
our hypothesis that the CCDC93 variant (rs17512204) encodes a pro-
tein with improved function.
The current study provides evidence for a role of CCDC93 in
human LDL metabolism, cardiovascular disease, and cardiovascular
mortality with molecular clues from in vitro and in vivo experiments
that is related to LDLR-mediated LDL-c clearance (Take home figure).
Proof that loss of function mutations in CCDC93 may cause familial
hypercholesterolaemia in man would strengthen our findings, but
mutations in CCDC22, another gene encoding for a protein of the
CCC complex, have been shown to cause hypercholesterolaemia.13
In conclusion, this study shows that large-scale genetic studies can
help us find other angles to study LDL metabolism. It has implicated
yet another pathway that was already known to control the activity
and/or functionality of LDLR, i.e. it is endosomal sorting and recycling
in humans. It remains to be seen whether this insight may lead to new
tools for pharmaceutical intervention, but it has been shown that it is
possible to pharmaceutically target the endosomal-sorting pathway
with small molecules.41
Supplementary material
Supplementary material is available at European Heart Journal online.
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Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ,
Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular dis-
ease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus
statement from the European Atherosclerosis Society Consensus Panel. Eur
Heart J 2017;38:2459–2472.
2. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9,
low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:
1264–1272.
3. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J,
Afonso L, Williams KA, Flack JM. Effect of long-term exposure to lower low-
density lipoprotein cholesterol beginning early in life on the risk of coronary
heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012;60:
2631–2639.
4. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L,
Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D,
Saleheen D, Ballantyne CM, Psaty BM, Sundström J, Ridker PM, Nagel D, Gillum
RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RPF, Assmann G,
D’Agostino RB, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW,
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Lindström J, Loos RJF, Mach F, McArdle WL, Meisinger C, Mitchell BD, Müller G,
Nagaraja R, Narisu N, Nieminen TVM, Nsubuga RN, Olafsson I, Ong KK, Palotie
A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM,
Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K,
Stancáková A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ,
Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsgaard T,
Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S,
Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet
P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen Y-DI, Collins FS,
Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci
L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllensten U, Hamsten A,
Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA,
Humphries SE, Hunt SC, Hveem K, Iribarren C, Järvelin M-R, Jula A, Kähönen M,
Kaprio J, Kesäniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D,
Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG,
März W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L,
Morris AD, Munroe PB, Njølstad I, Pedersen NL, Power C, Pramstaller PP, Price
JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera
DK, Saramies J, Schwarz PEH, Sheu WH-H, Shuldiner AR, Siegbahn A, Spector
TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M,
van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB,
Wolffenbuttel BHR, Ordovas JM, Boerwinkle E, Palmer CNA, Thorsteinsdottir
U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS,
Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis GR;
12 A. Rimbert et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz727/5599853 by U
niversity of G
roningen user on 26 N
ovem
ber 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..Global Lipids Genetics Consortium. Discovery and refinement of loci associated
with lipid levels. Nat Genet 2013;45:1274–1283.
10. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D,
Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes
TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M,
Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F,
Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen Y-D, Chowdhury R,
Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies
G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé M-P, Ebeling T,
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Pearson N, Danson CM, Nägele H, Morris LL, Singla A, Overlee BL, Heesom KJ,
Sessions R, Banks L, Collins BM, Berger I, Billadeau DD, Burstein E, Cullen PJ.
CCDC93, LDLR and cardiovascular protection 13
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz727/5599853 by U
niversity of G
roningen user on 26 N
ovem
ber 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.Retriever is a multiprotein complex for retromer-independent endosomal cargo
recycling. Nat Cell Biol 2017;19:1214–1225.
33. Wijers M, Zanoni P, Liv N, Vos DY, Jäckstein MY, Smit M, Wilbrink S, Wolters
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38. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope:
when selection bias can substantially influence observed associations. Int J
Epidemiol 2018;47:226–235.
39. Macfarlane GJ, Beasley M, Smith BH, Jones GT, Macfarlane TV. Can
large surveys conducted on highly selected populations provide valid in-
formation on the epidemiology of common health conditions? An ana-
lysis of UK Biobank data on musculoskeletal pain. Br J Pain 2015;9:
203–212.
40. Maine GN, Mao X, Muller PA, Komarck CM, Klomp LWJ, Burstein E. COMMD1
expression is controlled by critical residues that determine XIAP binding.
Biochem J 2009;417:601–609.
41. Mecozzi VJ, Berman DE, Simoes S, Vetanovetz C, Awal MR, Patel VM, Schneider
RT, Petsko GA, Ringe D, Small SA. Pharmacological chaperones stabilize retro-
mer to limit APP processing. Nat Chem Biol 2014;10:443–449.
14 A. Rimbert et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz727/5599853 by U
niversity of G
roningen user on 26 N
ovem
ber 2019
